证券代码：002603 证券简称：以岭药业 公告编号：2024-013 石家庄以岭药业股份有限公司 第八届董事会第十次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 石家庄以岭药业股份有限公司（以下简称"公司"）第八届董事会第十次会 议于 2024 年 6 月 3 日在公司会议室以现场方式结合通讯方式召开。本次会议通 知和文件于 2024 年 5 月 27 日以电话通知并电子邮件方式发出。会议应参加表决 董事 8 人，实际参加表决董事 8 人，其中陈刚先生以通讯方式参加。会议由公司 董事长吴相君主持，监事会成员、公司高级管理人员列席了会议。本次会议的召 集程序、审议程序和表决方式均符合《公司法》、相关法律法规及本公司章程的 规定。 会议以记名投票表决方式审议通过了以下议案并形成决议如下： 一、审议通过了《关于增补公司第八届董事会独立董事候选人的议案》。 根据《中华人民共和国公司法》《中华人民共和国证券法》以及《上市公司 章程指引（2023.12.15 修订）》《上市公司监管指引第 3 号——上市公司现金分红 （2023 修订）》等有关法律、行政法 ...

Investment Rating - The report assigns an "OUTPERFORM" rating to the company with a target price of RMB 22.62 [2][5]. Core Insights - The company reported a revenue of RMB 10.32 billion in 2023, a decrease of 17.67% year-on-year, and a net profit attributable to shareholders of RMB 1.35 billion, down 42.76% year-on-year [3][12]. - The decline in revenue was primarily due to decreased market demand for respiratory products, which saw a revenue drop of 51.90% to RMB 3.31 billion [4][13]. - Excluding respiratory products, other patented products showed stable growth, with cardiovascular products achieving a revenue of RMB 4.71 billion, an increase of 12.71% [4][13]. - The company has ongoing research and development efforts, with a focus on traditional Chinese medicine and several new drugs expected to be launched in the coming years [14][15]. Financial Performance Summary - In 2023, the company achieved a revenue of RMB 10.32 billion, with a year-on-year decline of 17.67% [6][9]. - The net profit for 2023 was RMB 1.35 billion, reflecting a decrease of 42.76% year-on-year [6][9]. - The earnings forecast for 2024-2026 predicts net profits of RMB 1.51 billion, RMB 1.80 billion, and RMB 2.13 billion, with respective year-on-year growth rates of 11.8%, 18.8%, and 18.6% [5][15]. Research and Development - The company invested RMB 0.94 billion in R&D in 2023, focusing on new drug development in traditional Chinese medicine and secondary development of existing products [14][15]. - Several new drugs are in various stages of clinical trials, with significant potential for future revenue growth [14][15]. Revenue Breakdown - Revenue from cardiovascular products was RMB 4.71 billion, up 12.71% year-on-year, while other patented products generated RMB 1.87 billion, an increase of 69.72% [4][13]. - The respiratory product segment faced a significant decline, contributing only RMB 3.31 billion to total revenue [4][13].

Summary of the Conference Call Company and Industry Involved - The conference call involved Huaren Pharmaceutical and its strategic discussion with investors [1] Core Points and Arguments - The meeting was hosted by the chief of the Huaren Pharmaceutical team, Mr. Tan Guochao [1] - The session included a presentation from company leadership, specifically Mr. Zhang, to engage with investors [1] - The discussion was structured into two main parts: company introduction and a Q&A session [1] Other Important but Possibly Overlooked Content - The call served as a follow-up to a previous exchange with Ling Pharmaceutical, indicating ongoing communication and collaboration within the industry [1]

北京市东城区建国门内大街 26 号新闻大厦 7 层、8 层 电话：010-88004488/66090088 传真：010-66090016 邮编：100005 北京国枫律师事务所 关于石家庄以岭药业股份有限公司 2023 年年度股东大会的 法律意见书 国枫律股字[2024]A0297 号 致：石家庄以岭药业股份有限公司（贵公司） 北京国枫律师事务所（以下简称"本所"）接受贵公司的委托，指派律师出席并见 证贵公司 2023 年年度股东大会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《上市公司股东大会规则》、《律师 事务所从事证券法律业务管理办法》（以下简称"《证券法律业务管理办法》"）、《律 师事务所证券法律业务执业规则（试行）》（以下简称"《证券法律业务执业规则》"） 等相关法律、行政法规、规章、规范性文件及《石家庄以岭药业股份有限公司章程》（以 下简称"《公司章程》"）的规定，就本次会议的召集与召开程序、召集人资格、出席 会议人员资格、会议表决程序及表决结果等事宜，出具本法律意见书。 对本法律意见书的出具 ...

中国国际金融股份有限公司 关于石家庄以岭药业股份有限公司 《关于 2023 年度募集资金存放与使用情况 的专项报告》的 核查意见 保荐机构 1 原中信银行股份有限公司石家庄休门街支行 | | | 二〇二四年四月 中国国际金融股份有限公司（以下简称"中金公司"）作为石家庄以岭药业股 份有限公司（以下简称"以岭药业"或"公司"）的保荐机构，根据《证券发行上市 保荐业务管理办法》《深圳证券交易所股票上市规则》《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》及《深圳证券交易所上市公司 自律监管指引第 13 号——保荐业务》等有关法律法规的要求，对以岭药业 2023 年度《石家庄以岭药业股份有限公司关于 2023 年度募集资金存放与使用情况的 专项报告》进行了核查，并出具本核查意见（以下简称"本意见"或"本核查意见"）。 一、募集资金基本情况 （一）实际募集资金金额、资金到位情况 公司经中国证券监督管理委员会《关于核准石家庄以岭药业股份有限公司非 公开发行股票的批复》（证监许可[2017] 81 号）核准，公司采用向特定投资者非 公开发行的方式发行每股面值为人民币 1.00 元的普通股股票 74, ...

石家庄以岭药业股份有限公司 证券代码：002603 证券简称：以岭药业 公告编号：2024-012 特别提示： 1、本次股东大会未出现否决议案的情形； 2、本次股东大会没有涉及变更前次股东大会决议。 一、会议召开和出席情况 （一）会议召开情况： 1、会议召开时间： （1）现场会议时间：2024 年 5 月 22 日下午 14:30 2023 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 （2）网络投票时间：2024 年 5 月 22 日。其中，通过深圳证券交易所交易 系统进行网络投票的时间为 2024 年 5 月 22 日上午 9:15—9:25，9:30—11:30，下 午 13:00—15:00；通过深圳证券交易所互联网投票系统投票的具体时间为 2024 年 5 月 22 日 9:15 至 15:00 的任意时间 2、会议地点：石家庄高新区天山大街 238 号以岭健康城会议室 3、会议召开方式：现场投票、网络投票相结合 4、会议召集人和主持人：公司董事会。董事长吴相君先生主持会议。 本次会议的召集、召开程序及表决方式符合有关法律、 ...

Summary of the Conference Call Company Overview - The conference call was hosted by the team from Huaren Pharmaceutical, led by Chief Pan Guochao, focusing on the listed company Yili Pharmaceutical [1] - The meeting included a discussion with company leadership, specifically Mr. Zhang, to provide insights into the company [1] Key Points and Arguments - The call was structured into two main parts: a company introduction and a Q&A session [1] Other Important Content - The event was described as a live strategy meeting held in conjunction with a camping event, indicating a unique approach to investor engagement [1]

Summary of the Conference Call Company and Industry Involved - The conference call involved Huazhong Medicine and its subsidiary Yili Pharmaceutical, focusing on the pharmaceutical industry [1] Core Points and Arguments - The meeting was hosted by the chief of the Huazhong Medicine team, Mr. Tan Guochao, and included a presentation from the leadership of Yili Pharmaceutical, represented by Mr. Zhang [1] - The discussion was structured into two main parts: a company introduction and a Q&A session [1] Other Important but Possibly Overlooked Content - The event was characterized as a summer on-site strategy meeting, indicating a focus on strategic planning and investor engagement [1]

Group 1: Financial Performance - The company's revenue and net profit for 2023 decreased by 7.67% and 42.76% respectively, primarily due to a significant decline in sales of the Lianhua Qingwen product and increased costs of traditional Chinese medicine materials [6][8]. - The company reported other income of 1.8 billion with a growth rate of 69% in the previous year [2]. - The company plans to maintain a stable gross profit margin through cost reduction and efficiency improvement measures [2][6]. Group 2: Market Strategy - The company aims to enhance its retail channel strategy by establishing a dedicated sales team for retail terminals and implementing a combination marketing strategy [2][3]. - The market share of the company's innovative patent Chinese medicines, including Tongxinluo Capsule, Shenmai Injection, and Qiliqiangxin Capsule, increased from 13.64% in 2015 to 16.39% in the first half of 2023 [10]. - The company is focusing on expanding its product line and entering new treatment areas to seize long-term development opportunities in the industry [9]. Group 3: Research and Development - The company has established a national key laboratory for the innovation and transformation of the Luo disease theory, which has led to the development of 14 innovative patent Chinese medicines [3][9]. - The company has completed the filing of 246 national standard Chinese medicine formula granules and 333 provincial standard formula granules, with a high rate of compliance in various provinces [12]. - The company is actively pursuing internationalization by enhancing the brand influence of traditional Chinese medicine and establishing over 130 professional committees abroad [3]. Group 4: Investor Relations - The company has no current plans for stock repurchase, citing various market factors affecting stock prices [4][9]. - The actual controller's stock pledge is low and poses no risk to the company's control or operations [9][11]. - The company emphasizes the importance of cash dividends as a way to return value to shareholders, aligning with long-term sustainable development [13].

Investment Rating - The investment rating for the company is "Outperform the Market" [1] Core Views - The company reported a revenue of 10.318 billion yuan in 2023, a decrease of 17.67% year-on-year, and a net profit of 1.352 billion yuan, down 42.76% [4][6] - The decline in revenue is attributed to decreased market demand for respiratory products due to high inventory levels and a high base from the previous year [4] - Despite the decline in respiratory products, other patented products, particularly in cardiovascular and other categories, showed stable growth [5][6] - The company has invested 935 million yuan in R&D, focusing on new drug development and secondary development of existing products [5][6] Financial Summary - Revenue for 2023 was 10.318 billion yuan, with a projected increase to 10.923 billion yuan in 2024, representing a year-on-year growth of 5.9% [6][9] - Net profit is expected to recover to 1.512 billion yuan in 2024, reflecting an 11.8% increase from 2023 [6][9] - The company’s gross margin for 2023 was 57.3%, with a slight decrease projected to 56.9% in 2024 [6][9] Product Performance - Revenue from respiratory products in 2023 was 3.305 billion yuan, a significant decline of 51.90% [5][6] - Cardiovascular products generated 4.709 billion yuan in revenue, marking a growth of 12.71% [5][6] - Other patented products saw a revenue increase of 69.72%, totaling 1.869 billion yuan [5][6] R&D and Future Prospects - The company has multiple new drugs in various stages of clinical trials, with significant focus on traditional Chinese medicine [5][6] - The forecast for net profit from 2024 to 2026 is 1.512 billion yuan, 1.796 billion yuan, and 2.130 billion yuan, respectively, indicating a positive growth trajectory [6][9] - The company is expected to maintain a unique product layout in the cardiovascular and respiratory fields, supported by ongoing R&D efforts [5][6]